Wree A, Broderick L, Canbay A, Hoffman HM, Feldstein AE. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol. 2013;10(11):627–36.

Article  CAS  PubMed  Google Scholar 

Brunt EM, Wong VWS, Nobili V, Day CP, Sookoian S, Maher JJ, et al. Nonalcoholic fatty liver disease. Nature Rev Disease Primers. 2015;1(1):1–22.

Article  Google Scholar 

Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, et al. Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(6):1717–30.

Article  PubMed  Google Scholar 

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.

Article  PubMed  Google Scholar 

Noureddin M, Ntanios F, Malhotra D, Hoover K, Emir B, McLeod E et al. 2022 Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017–2018 transient elastography data and application of machine learning. Hepatol Commun. 6(7): 1537–48. https://doi.org/10.1002/hep4.1935.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shalimar EA, Bansal B, Gupta H, Anand A, Singh TP, et al. Prevalence of non-alcoholic fatty liver disease in India: a systematic review and meta-analysis. J Clin Exp Hepatol. 2022;12(3):818–29.

Article  CAS  PubMed  Google Scholar 

Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547–54.

Article  CAS  PubMed  Google Scholar 

Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–9.

Article  PubMed  Google Scholar 

Britton LJ, Subramaniam VN, Crawford DHG. Iron and non-alcoholic fatty liver disease. World J Gastroenterol. 2016;22(36):8112.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mehta KJ, Je Farnaud S, Sharp PA. Iron and liver fibrosis: mechanistic and clinical aspects. World J Gastroenterol. 2019;25(5):521.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kowdley KV. Iron overload in patients with chronic liver disease. Gastroenterol Hepatol (N Y). 2016;12(11):695.

PubMed  Google Scholar 

Ramm GA, Britton RS, O’Neill R, Bacon BR. Identification and characterization of a receptor for tissue ferritin on activated rat lipocytes. J Clin Investig. 1994;94(1):9–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ruddell RG, Hoang-Le D, Barwood JM, Rutherford PS, Piva TJ, Watters DJ, et al. Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappaB–regulated signaling in rat hepatic stellate cells. Hepatology. 2009;49(3):887–900.

Article  CAS  PubMed  Google Scholar 

Mao Q, Xie Z, Wang X, Chen W, Ren M, Shang M, et al. Clonorchis sinensis ferritin heavy chain triggers free radicals and mediates inflammation signaling in human hepatic stellate cells. Parasitol Res. 2015;114(2):659–70.

Article  PubMed  Google Scholar 

Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA, Chalasani N, et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2012;55(1):77–85.

Article  CAS  PubMed  Google Scholar 

Jung JY, Shim JJ, Park SK, Ryoo JH, Choi JM, Oh IH, et al. Serum ferritin level is associated with liver steatosis and fibrosis in Korean general population. Hepatol Int. 2019;13(2):222–33. https://doi.org/10.1007/s12072-018-9892-8.

Article  PubMed  Google Scholar 

Buzzetti E, Petta S, Manuguerra R, Luong TV, Cabibi D, Corradini E, et al. Evaluating the association of serum ferritin and hepatic iron with disease severity in non-alcoholic fatty liver disease. Liver Int. 2019;39(7):1325–34. https://doi.org/10.1111/liv.14096.

Article  CAS  PubMed  Google Scholar 

Hagström H, Nasr P, Bottai M, Ekstedt M, Kechagias S, Hultcrantz R, et al. Elevated serum ferritin is associated with increased mortality in non-alcoholic fatty liver disease after 16 years of follow-up. Liver Int. 2016;36(11):1688–95.

Article  PubMed  Google Scholar 

Yang N, Lu Y, Cao L, Lu M. The association between non-alcoholic fatty liver disease and serum ferritin levels in American adults. J Clin Lab Anal. 2022;36(2): e24225.

Article  CAS  Google Scholar 

NHANES 2017-March (2020) Pre-pandemic laboratory data [Internet]. [cited 2022 Oct 11]. Accessed from https://wwwn.cdc.gov/nchs/nhanes/search/datapage.aspx?Component=Laboratory&Cycle=2017-2020

Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67(1):328–57.

Article  PubMed  Google Scholar 

Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart association/national heart, lung, and blood institute scientific statement. Circulation. 2005;112(17):2735–52.

Article  PubMed  Google Scholar 

ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. Classification and diagnosis of diabetes: standards of care in diabetes—2023. Diabetes Care. 2023;46(Supplement_1):19–40.

Article  Google Scholar 

Overweight & Obesity | CDC. Defining adult overweight & obesity. [cited 2023 Feb 3]. Available from: https://www.cdc.gov/obesity/basics/adult-defining.html.

Wang W, Knovich MA, Coffman LG, Torti FM, Torti SV. Serum ferritin: past, present and future. Biochim Biophys Acta. 2010;1800:760.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Camaschella C, Nai A, Silvestri L. Iron metabolism and iron disorders revisited in the hepcidin era. Haematologica. 2020;105(2):260–72.

Article  PubMed  PubMed Central  Google Scholar 

Yang HH, Chen GC, Li DM, Lan L, Chen LH, Xu JY, et al. Serum iron and risk of nonalcoholic fatty liver disease and advanced hepatic fibrosis in US adults. Sci Rep. 2021;11:10387.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li L, Zhu Z (2022) Pharmacological modulation of ferroptosis as a therapeutic target for liver fibrosis. Front Pharmacol. 13: 1071844.

Fargion S, Mattioli M, Ludovica Fracanzani A, Sampietro M, Tavazzi D, Fociani P, et al. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol. 2001;96(8):2448–55.

Article  CAS  PubMed  Google Scholar